As the promise of psychedelic investments expands in North America, Australian investors are getting a tease on what could be coming down the line.

Last Friday (June 19), market participants were treated to presentations from three participants in the quickly growing psychedelic drug industry. The event was hosted by Melbourne-based investment and portfolio management firm Peak Asset Management.

The online presenters included: Peter Hunt, chairman of Mind Medicine Australia; Jonathan Gilbert, CEO and director of Eleusian Biosciences; and Steve McAuly, chairman and CEO of Empower Clinics (CSE:CBDT,OTCQB:EPWCF).


BRAND NEW! Take Advantage Of Silver On The Rise Before It's Too Late

Everything You Need To Watch The Dollars Come Pouring In!

Gilbert started by breaking down his heavy involvement in the alternative drug market, telling the audience that Eleusian isn’t his first foray into psychedelics.

Before his latest venture, Gilbert was involved as CEO of Tassili Life Sciences, a psychedelics research firm. Tassili went on to be acquired by Champignon Brands (CSE:SHRM,OTCQB:SHRMF) earlier this year.

Similar to Gilbert’s former venture, Eleusian is a research-focused operation investigating the medical benefits of psychedelic compounds. But unlike Tassili, Eleusian will become a public entity by way of an all-hands acquisition deal with GreenStar Biosciences (CSE:GSTR,OTC Pink:GTSIF).

When asked about the potential for a listing in the Australian markets, Gilbert said it would be worth exploring in the future, although he didn’t confirm an official announcement.

From an advocacy perspective, Hunt spoke at length about the current opportunity attached to the medical use of psychedelics in Australia as an alternative to treat various mental health conditions.

As per official data shown by Hunt, one in five Australian adults deals with a chronic mental illness, or about 4.8 million people. Based on a draft report by the Australian Productivity Commission, the total cost of mental illness and suicides to the Australian economy in 2019 was an estimated AU$180 billion.

Mind Medicine Australia, which has no relation to Mind Medicine (MindMed) (NEO:MMED), a public Canadian firm bearing the same name, is a non-profit group seeking to advance the conversation on psychedelics as a viable medicine alternative for patients.

Hunt said while there is currently no university-sanctioned research being done in the country around psychedelic compounds, such as psilocybin and MDMA, Mind Medicine Australia hopes to announce a critical partnership in the near future.

As the last presenter of the session, McAuly broke down how his firm has focused on an expansion into psychedelics; the firm primarily operates as a cannabidiol (CBD) product manufacturer in the US.

Empower Clinics manages a network of health and wellness clinics in the US, offering an array of products and services. Earlier in 2020, the firm launched a venture into psychedelics dubbed Dosed Wellness. The move followed a partial rights stake purchase for the independent documentary film DOSED, which follows the recovery path of a woman using mushroom medicine.

Investor takeaway

As Hunt indicated, the Australian market is in the very early stages in terms of availability and acceptance of psychedelic investments. However, it’s unquestionable that this investment trend is starting to expand across the globe.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


BRAND NEW! Take Advantage Of Silver On The Rise Before It's Too Late

Everything You Need To Watch The Dollars Come Pouring In!

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 91st nationwide.

The latest dispensary, located in Winter Park , supports Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The dispensary expands access throughout Central Florida , joining four locations throughout nearby Orlando .

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis extractor, is pleased to announce that the United States Patent and Trademark Office has granted the Company a patent pertaining to the extraction and purification of THC and CBD.

The Company believes it has developed defendable intellectual property around the most efficient methods for producing THC and CBD distillate at scale within a regulated market. Nextleaf owns 15 U.S. patents and has been issued over 80 patents globally.

Keep reading... Show less

Cannabis Company Executives share vision, answer questions live at

Virtual Investor Conferences in partnership with KCSA Strategic Communications and ATB Capital Markets today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 9:30 AM ET on Tuesday June 29 th .

Keep reading... Show less

Acquisition solidifies Canopy Growth’s leadership position in the Canadian recreational market

Canopy Growth Corporation (“Canopy”) (TSX: WEED) (NASDAQ: CGC) and The Supreme Cannabis Company, Inc. (“Supreme”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) are pleased to announce the completion of the previously announced arrangement (the “Arrangement”) whereby Canopy has acquired all of the issued and outstanding common shares of Supreme (the “Supreme Shares”).

Keep reading... Show less